Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis

Autor: Lyn Guenther, Irina Turchin, Ron Vender, Lorne E. Albrecht, Catherine Maari, Howard Yanofsky, Vimal H. Prajapati

Publikováno v: Dermatology and Therapy, Vol 14, Iss 7, Pp 1917-1928 (2024)

Abstract Introduction An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose comb

Externí odkaz: https://doaj.org/article/9a376251ab6747ba8d8b8b1dd9ba6f63

Psoriasis, biologic therapy, and the pandemic of the 21st century

Autor: Miguel Nogueira, Ron Vender, Tiago Torres

Publikováno v: Drugs in Context, Vol 9, Pp 1-4 (2020)

The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood

Externí odkaz: https://doaj.org/article/17488b352a00423387b050fba6fc0549

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis:longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

Autor: Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B Kimball

Publikováno v: Tha?i, D, Vender, R, de Rie, M A, Conrad, C, Pariser, D M, Strober, B, Vanvoorden, V, Wang, M, Madden, C, de Cuyper, D & Kimball, A B 2023, ' Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis : longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial ', British Journal of Dermatology, vol. 188, no. 1, pp. 22-31 . https://doi.org/10.1093/bjd/ljac021
British Journal of Dermatology, 188(1), 22-31. Wiley-Blackwell

Background BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings. Objectives To provide efficacy and safety data over 2 years of bimekizumab treatment compared with adalim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9987cd699828d991ef25e576c63d8b1f
https://research.vumc.nl/en/publications/a9a82c67-83e7-4154-8697-655c76349821

Management of moderate-to-severe plaque psoriasis with biologics: A treat-to-target position paper

Autor: Jensen Yeung, Marc Bourcier, Melinda J. Gooderham, Parbeer Grewal, Chih‐Ho Hong, Perla Lansang, Charles Lynde, Catherine Maari, Vimal H. Prajapati, Irina Turchin, Ron Vender

Publikováno v: Dermatologic therapyREFERENCES. 35(10)

Treat-to-target (T2T) recommendations for the use of systemic therapies (including biologics) in patients with moderate-to-severe plaque psoriasis have been published by a few groups of experts worldwide. However, there remains considerable variabili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2ccdda463986a73c12215dd9e2f332b
https://pubmed.ncbi.nlm.nih.gov/35988045

Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension

Autor: Diamant Thaçi, Ron Vender, Menno De Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Wang, Nancy Cross, Delphine Deherder, Natalie Nunez Gomez, Alice B Gottlieb

Publikováno v: SKIN The Journal of Cutaneous Medicine. 6:s68

N/A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d5e1ffacba3552c140348e64f8461b8
https://doi.org/10.25251/skin.6.supp.68